– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced hybrid closed-loop algorithm. Control-IQ+, compatible ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem ...

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

“Testing the limits of pump miniaturization, Tandem Mobi joins the t:slim X2 pump in our family of insulin delivery solutions bringing new options in wearability, the flexibility to disconnect, and ...

CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...

Tandem Diabetes Care Inc.’s Control-IQ+ automated insulin delivery system improved multiple measures of glycemic control in individuals with type 2 diabetes who use insulin, a study presented March 19 ...